PRGO · PERRIGO COMPANY PLC

The thesis

Perrigo's recovery case weakened on 4 November 2026, when the company cut 2026 core adjusted earnings-per-share guidance to $2.15–$2.35 from $2.25–$2.55. The shares look more likely to lag the S&P 500 than lead it until the Oral Care review or the fourth-quarter report, expected around late February 2027, shows earnings and debt both improving. A confirmed takeover offer or an Oral Care sale with substantial upfront cash would show that view is wrong.

The cut took the bottom of the range below $2.25, the earnings condition named in the previous note. The debt side moved less than a signed sale first suggests. The Infant Formula agreement of 29 October 2026 is worth up to $175 million, but only $40 million is cash at closing, and closing is expected in the first half of 2027. Total debt stood at about $3.3 billion on 26 September 2026, per the third-quarter release.

The narrative is maturing: the disposal plan is well known, its Infant Formula step was signed on 29 October 2026, and the 4 November 2026 guidance cut removed the earnings range that supported the story. The shares closed at $15.71 on 5 November 2026 (split- and dividend-adjusted daily closes).

Bullish and bearish views on PERRIGO COMPANY PLC

The bull case on PERRIGO COMPANY PLC (PRGO), in brief: Organic sales decline narrowed. The bear case: Guidance fell on the like-for-like measure.

Bull case

• Organic sales decline narrowed. Third-quarter core organic net sales fell 1.1%, per the 4 November 2026 release, after a 3.5% fall in the second quarter.
• Cash flow improved in the quarter. Operating cash flow was $96 million in the third quarter, which brought the nine-month figure to $65.2 million from negative $31 million at the half. The 4 November 2026 release and Form 10-Q report both numbers.
• A low-margin business is leaving. Infant Formula earned $8 million of segment adjusted operating income on $380 million of net sales in the four quarters to 27 June 2026, per the 29 October 2026 announcement. Perrigo expects the sale to lift margins and materially reduce future capital spending.
• Oral Care is still in play. The 4 November 2026 release says the strategic review of Oral Care remains ongoing. A sale with disclosed cash would add to the roughly $366 million of net business-sale proceeds reported for the first nine months.
• One analyst target sits above the shares. Canaccord Genuity kept its Buy rating and raised its target to $19 on 31 October 2026, before the guidance cut. Betaville's unconfirmed 9 October 2026 report that CVC Capital may be weighing a purchase also remains in the background, and Perrigo has confirmed no approach.

Bear case

• Guidance fell on the like-for-like measure. Core adjusted earnings-per-share guidance fell to $2.15–$2.35 on 4 November 2026. Core organic net-sales guidance moved to a decline of 2.7%–3.8%, from a range of a 3.0% decline to 1.0% growth. The release cites more measured retailer ordering before cough and cold season and continued softness in Europe.
• The sale brings little near-term cash. MeridianMade pays $40 million at closing, with up to $135 million contingent on net-sales milestones through 2030. Perrigo expects a non-cash impairment of $275–$375 million in the fourth quarter of 2026.
• Debt remains large. Long-term debt was $3,282.8 million and current debt $11.3 million against $436.6 million of cash on 26 September 2026, per the Form 10-Q. The 2026 outlook assumes net leverage of about 4.0 times adjusted earnings before interest, tax, depreciation and amortisation, and net interest expense of about $162 million.
• Dividends exceed operating cash flow so far. Cash dividends totalled $120.3 million in the first nine months of 2026, against $65.2 million of operating cash flow (Form 10-Q). Perrigo paid $0.29 a share in each quarter shown and declared another quarterly dividend on 29 October 2026.
• Main segments lost profit. Self Care adjusted operating income fell 19.4% to $105 million in the third quarter, and Specialty Care fell 24.2% to $32 million. The All Other segment rose 18.4% to $27 million with help from a tariff recovery.
• Write-downs and legal costs persist. The Form 10-Q shows a nine-month net loss of $351.6 million, $335.9 million of impairment charges, and a $61.0 million accrual for price-fixing lawsuits. Oral Care goodwill has been written down to zero after a $187.2 million impairment in 2026.
• Leadership remains interim. The 4 November 2026 release still names Albert Manzone as interim chief executive. A permanent appointee could change the disposal plan.

Price setup

The adjusted daily close was $15.71 on 5 November 2026, against $16.37 on 22 October 2026 and $15.06 on 9 October 2026, the day of Betaville's CVC report. The shares sit 5.5% below the $16.63 52-week high and are up 26.2% over three months. The $20.51 high cited in the previous note has left the 52-week window, so the smaller gap reflects older prices dropping out.

The 14-day relative strength index, a 0–100 momentum gauge, fell to 32.7 on 5 November 2026 from 71.8 on 22 October 2026. Readings near 30 are commonly described as oversold. Momentum has cooled sharply since the Infant Formula and earnings news.

Crowding evidence is mixed. A Smartkarma note dated 15 October 2026 put short interest near 17%, which can amplify moves in either direction. No company earnings date falls in the next 30 days. A close below $15.06 would return the shares to where they stood on the day of the CVC report. A weekly close below $13.00 would erase most of the three-month rise.

Catalysts, next 30 days

• ~25 February 2027, est.: fourth-quarter and full-year 2026 results, date unconfirmed. They show whether core adjusted earnings per share lands inside $2.15–$2.35 and how large the Infant Formula impairment is.
• First half of 2027, company estimate: the Infant Formula sale closes, subject to customary conditions and regulatory approvals. It delivers the $40 million of upfront cash.
• Undated: an outcome of the Oral Care review, or a permanent chief executive appointment. Either could change the debt path or the disposal plan.

Elapsed catalysts

• Next 30 days: company news through 5 November 2026 shows no confirmed earnings, regulatory or transaction date. (passed 1d ago)

What would change the view

The remaining recovery case breaks if reported 2026 core adjusted earnings per share falls below $2.15, or if the Oral Care review ends with no transaction and debt stays near $3.3 billion. A return to steeper core organic declines than the 1.1% fall of the third quarter would also weaken it. On price, a weekly close below $13.00 would end the case.

The view that the shares lag the S&P 500 would be wrong if Perrigo confirms a takeover offer or signs an Oral Care sale with substantial upfront cash. A fourth-quarter report above the middle of the core range, with lower debt and positive cash flow after dividends, would also contradict it.

What it trades with

The shares trade mainly on company events: guidance, disposals and takeover reports. The 9 October 2026 CVC report lifted them about 4% that day, per Seeking Alpha. The operating links are retailer ordering ahead of cough and cold season and the European consumer, both named in the 4 November 2026 release. Debt of about $3.3 billion and about $162 million of expected net interest expense also tie the equity to financing costs.